Möchten Sie immer auf dem neuesten Stand bleiben?

- Primary endpoint achieved by both DURAVYU doses (1.34mg and 2.7mg) with extended time to first supplemental injection versus aflibercept control – - DURAVYU 2.7mg demonstrated an early and...

Own every video meeting with the latest version of mmhmm.

ONAPGO is the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced Parkinson’s diseaseONAPGO is a wearable subcutaneous infusion...

MIAMI, FL, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high...

Three drill holes that tested the extensions of the Jubilee Shear at depth intersected quartz veins with visible gold approximately 170 m and 100 m away.

As seen in the DESTINY-Breast06 trial, approximately 20-25 percent of hormone receptor (HR)-positive, HER2-negative breast cancer patients may be considered HER2-ultralow.1 These patients may now be...

Mobile, AL , Jan. 30, 2025 (GLOBE NEWSWIRE) -- Managing rental properties has never been easier for South Alabama property owners, thanks to The Rent Experts. Specializing in professional property...

SquareX discloses a new attack technique that shows how malicious extensions can be used to completely hijack the browser, and eventually, the whole device. PALO ALTO, Calif., Jan. 30, 2025 ...

29 January 202 Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful. ENGINEERING INGEGNERIA INFORMATICA S.P.A. ...

-- Study met primary endpoint: Enobosarm treatment resulted in statistically significant reduction in the loss of lean mass in subjects receiving WEGOVY (p=0.002) -- -- Patients on Enobosarm on...